Gleevec keeps Cancer Patients alive 10  Years More
Channel: Qud Mohamed
Date: 2017-03-10

A 2001-FDA approved cancer drug, Gleevec, has been hailed as the new wonder drug for adding at least 10 more years to the lives of cancer patients. Also known as imatinib, the drug was developed by Novartis Pharmaceuticals as a targeted drug to treat chronic myeloid leukemia (CML). A new study published in the New England Journal of Medicine reveals that no additional health risks have been found for the drug nearly 17 years after its introduction into the market.
A CML diagnosis amounted to a death sentence

CML is a type of leukemia or blood cancer. According to the US National Cancer Institute (NCI), being diagnosed with the condition before the introduction of Gleevec was tantamount to a death sentence. This however is no longer the case since cancer patients now live above 10 years post-treatment with the drug.
http://www.itechpost.com/articles/90912/20170310/gleevec-cancer-patients-hope-live-10-more-years-despite-ailments.htm

The drug was hailed as a wonder drug for patients with CML, a type of blood cancer that affects about 5,000 in the United States per year. Before the Food and Drug Administration approved the drug, less than one in three patients with CML survived five years after their diagnosis.

Now, a new study gives credence to Gleevec being a wonder drug. Findings of the study, which were published in the New England Journal Medicine on Thursday, March 9, revealed that the drug can keep patients alive for 10 years or more.
http://www.techtimes.com/articles/200977/20170309/cancer-pill-can-keep-leukemia-patients-alive-for-more-than-10-years.htm